Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of bevacizumab in refractory solid tumors

Trial Profile

A phase I study of bevacizumab in refractory solid tumors

Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 06 Jun 2017 Results of an integrated analysis assessing the effects of bevacizumab on growth/development in pediatric/adolescent patients (n=403), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top